Abstract
Background: Statin treatment exhibits a beneficial effect on non-alcoholic fatty liver disease (NAFLD) and on cardiovascular disease (CVD) in patients with NAFLD.
Objective: The aim of this review is to summarize the role of proprotein convertase subtilisin kexin type- 9(PCSK9) in the pathogenesis of NAFLD and discuss the effects of the new hypolipidaemic drugs PCSK9 inhibitors on NAFLD.
Results: Data indicates that high intrahepatic or circulating PCSK9 levels increase muscle and liver lipid storage, adipose energy storage and hepatic fatty acids, as well as triglycerides storage and secretion, thus contributing to the pathogenesis of NAFLD. The findings of animal and human studies, aiming to reduce PCSK9 with inhibitors (human IGG antibodies, antisense particles against PCSK9 mRNA, and small anti PCSK9 antibodies) point towards liver protection from NAFLD through inhibition of PCSK9 expression in the induction of degradation of hepatic HNF1a protein, insulin resistance (IR), and other mechanisms.
Conclusions: The use of PCSK9 inhibitors ameliorates NAFLD, aside from beneficial effects on CVD and independently of low density lipoprotein cholesterol level reduction.
Keywords: PCSK9 inhibitors, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, familial hypercholesterolemia, statin, cardiovascular disease.
Current Pharmaceutical Design
Title:The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors
Volume: 24 Issue: 31
Author(s): Eleni Theocharidou*, Marianna Papademetriou, Andromachi Reklou, Alexandros Sachinidis, Chrisoula Boutari and Olga Giouleme
Affiliation:
- Institute of Liver Studies, King's College Hospital, Denmark Hill, SE5 9RS,United Kingdom
Keywords: PCSK9 inhibitors, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, familial hypercholesterolemia, statin, cardiovascular disease.
Abstract: Background: Statin treatment exhibits a beneficial effect on non-alcoholic fatty liver disease (NAFLD) and on cardiovascular disease (CVD) in patients with NAFLD.
Objective: The aim of this review is to summarize the role of proprotein convertase subtilisin kexin type- 9(PCSK9) in the pathogenesis of NAFLD and discuss the effects of the new hypolipidaemic drugs PCSK9 inhibitors on NAFLD.
Results: Data indicates that high intrahepatic or circulating PCSK9 levels increase muscle and liver lipid storage, adipose energy storage and hepatic fatty acids, as well as triglycerides storage and secretion, thus contributing to the pathogenesis of NAFLD. The findings of animal and human studies, aiming to reduce PCSK9 with inhibitors (human IGG antibodies, antisense particles against PCSK9 mRNA, and small anti PCSK9 antibodies) point towards liver protection from NAFLD through inhibition of PCSK9 expression in the induction of degradation of hepatic HNF1a protein, insulin resistance (IR), and other mechanisms.
Conclusions: The use of PCSK9 inhibitors ameliorates NAFLD, aside from beneficial effects on CVD and independently of low density lipoprotein cholesterol level reduction.
Export Options
About this article
Cite this article as:
Theocharidou Eleni *, Papademetriou Marianna , Reklou Andromachi , Sachinidis Alexandros, Boutari Chrisoula and Giouleme Olga , The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors, Current Pharmaceutical Design 2018; 24 (31) . https://dx.doi.org/10.2174/1381612824666181010123127
DOI https://dx.doi.org/10.2174/1381612824666181010123127 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Use of Protein Tyrosine Phosphatase Inhibitors as Promising Targeted Therapeutic Drugs
Current Medicinal Chemistry Epigenetic and Genetic Mechanisms of Abnormal 11p15 Genomic Imprinting in Silver-Russell and Beckwith-Wiedemann Syndromes
Current Medicinal Chemistry Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy
Current Drug Targets Strategy for a Genetic Assessment of Antipsychotic and Antidepressant- Related Proarrhythmia
Current Medicinal Chemistry Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis
Current Drug Metabolism Atherosclerotic Coronary Heart Disease Epidemiology, Classification and Management
Cardiovascular & Hematological Disorders-Drug Targets A Review of the Hypoglycemic Effects of Five Commonly Used Herbal Food Supplements
Recent Patents on Food, Nutrition & Agriculture CYP2A5 Induction and Hepatocellular Stress: An Adaptive Response to Perturbations of Heme Homeostasis
Current Drug Metabolism Pharmacovigilance and the Cardiovascular System: Two Sides to Every Story
Current Drug Safety Phenomics of Vascular Disease: The Systematic Approach to the Combination Therapy
Current Vascular Pharmacology Regulating the Beta Cell Mass as a Strategy for Type-2 Diabetes Treatment
Current Drug Targets Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Pathogenesis and Treatment Options
Current Vascular Pharmacology The Application of NMR Spectroscopy for the Study of Heart Failure
Current Pharmaceutical Design Potential Phytotherapeutic Approaches for the Treatment of Alzheimer’s Disease: An Overview
Current Traditional Medicine Appreciating the Balance between Classical Interleukin (IL)-6 Receptor Signaling and IL-6 Trans-Signaling: Implications for Arthritis Progression
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Recent updates on the dynamic association between oxidative stress and neurodegenerative disorders
CNS & Neurological Disorders - Drug Targets Hypertension and Childhood Obesity: A Whirling Tango. A Review of the Dance Steps
Current Hypertension Reviews Preparation and Evaluation of Multi Particulates Drug Delivery System Using Natural Polymers
Current Drug Delivery Vitamin D Status in Egyptian Adolescent Females with Iron Deficiency Anemia and Its Correlation with Serum Iron Indices
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Hyperglycaemia in Pathogenesis of Diabetic Cardiovascular Disease
Vascular Disease Prevention (Discontinued)